Evidence map›Paper›PMID 35565397›Full record

ReviewCancers2022

Upper Gastrointestinal Cancer and Liver Cirrhosis.

Kuo-Shyang Jeng, Chiung-Fang Chang, I-Shyan Sheen, Chi-Juei Jeng, Chih-Hsuan Wang

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Bangkok declarations on cancer control in Asia.The Lancet regional health. Western Pacific · 2025
    Review
  7. Review
  8. Article
  9. Natural Compounds for Preventing Age-Related Diseases and Cancers.International journal of molecular sciences · 2024
    Review
  10. Does Portal Hypertension Increase the Risk ofJournal of clinical medicine · 2024
    Article
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Kuo-Shyang JengDivision of General Surgery, Far Eastern Memorial Hospital, New Taipei City 22060, Taiwan.
Chiung-Fang ChangDivision of General Surgery, Far Eastern Memorial Hospital, New Taipei City 22060, Taiwan.ORCID 0000-0002-8741-5174
I-Shyan SheenDepartment of Hepato Gastroenterology, Chang-Gung Memorial Hospital, Linkou Medical Center, Taoyuan City 33305, Taiwan.
Chi-Juei JengPostgraduate Institute of Medicine, National Taiwan University, Taipei 10617, Taiwan.
Chih-Hsuan WangDivision of General Surgery, Far Eastern Memorial Hospital, New Taipei City 22060, Taiwan.
Far Eastern Memorial Hospital · TWChang Gung Memorial Hospital · TWNational Taiwan University · TW

Funding

Far Eastern Memorial Hospital FEMH-110-2314-B-418-009Ministry of Science and Technology MOST 110-2314-B-418-009
6 · The paper itself

Abstract

The extended scope of upper gastrointestinal cancer can include esophageal cancer, gastric cancer and pancreatic cancer. A higher incidence rate of gastric cancer and esophageal cancer in patients with liver cirrhosis has been reported. It is attributable to four possible causes which exist in cirrhotic patients, including a higher prevalence of gastric ulcers and congestive gastropathy, zinc deficiency, alcohol drinking and tobacco use and coexisting gut microbiota. Helicobacter pylori infection enhances the development of gastric cancer. In addition, Helicobacter pylori, Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans also contribute to the development of pancreatic cancer in cirrhotic patients. Cirrhotic patients (especially those with alcoholic liver cirrhosis) who undergo liver transplantation have a higher overall risk of developing de novo malignancies. Most de novo malignancies are upper gastrointestinal malignancies. The prognosis is usually poor. Considering the surgical risk of upper gastrointestinal cancer among those with liver cirrhosis, a radical gastrectomy with D1 or D2 lymph node dissection can be undertaken in Child class A patients. D1 lymph node dissection can be performed in Child class B patients. Endoscopic submucosal dissection for gastric cancer or esophageal cancer can be undertaken safely in selected cirrhotic patients. In Child class C patients, a radical gastrectomy is potentially fatal. Pancreatic radical surgery should be avoided in those with liver cirrhosis with Child class B or a MELD score over 15. The current review focuses on the recent reports on some factors in liver cirrhosis that contribute to the development of upper gastrointestinal cancer. Quitting alcohol drinking and tobacco use is important. How to decrease the risk of the development of gastrointestinal cancer in those with liver cirrhosis remains a challenging problem.

Indexed as

alcohol and tobaccogut microbiotaliver cirrhosisupper gastrointestinal cancerzinc

Identifiers

PMID35565397
PMCPMC9105927
OpenAlexW4225289823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.